Dr. David D. Suh, MD
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Medical school
- Medical College of Georgia School of Medicine (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 738
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: Medical College of Georgia School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
GA license 045340 · GA license 057848 · OH license 35080083
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Emory Decatur Hospital Decatur, GA
- Emory Hillandale Hospital Lithonia, GA
Medical groups
- Atlanta Heart Specialists LLC (21 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 738
- Services billed
- 5,800
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 1,313 | 619 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 808 | 564 |
| Injection, regadenoson, 0.1 mg | 420 | 104 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 328 | 162 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 272 | 265 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 188 | 179 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 164 | 162 |
| Insertion of needle into vein for collection of blood sample | 100 | 77 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 83 | 32 |
| New patient office or other outpatient visit, 45-59 minutes | 66 | 66 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Atorvastatin Calcium Other prescribers in Tucker, GA | 1,251 |
| Metoprolol Succinate Other prescribers in Tucker, GA | 934 |
| Carvedilol Other prescribers in Tucker, GA | 917 |
| Losartan Potassium Other prescribers in Tucker, GA | 719 |
| Amlodipine Besylate Other prescribers in Tucker, GA | 648 |
| Eliquis (apixaban) Other prescribers in Tucker, GA | 597 |
| Rosuvastatin Calcium Other prescribers in Tucker, GA | 593 |
| Spironolactone Other prescribers in Tucker, GA | 423 |
| Clopidogrel (clopidogrel bisulfate) Other prescribers in Tucker, GA | 380 |
| Lisinopril Other prescribers in Tucker, GA | 304 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 16 companies reported 51 payments worth $1,295 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $248 |
|---|---|
| Actelion Pharmaceuticals US, Inc. | $185 |
| Bridgebio Pharma, Inc. | $152 |
| Merck Sharp & Dohme LLC | $120 |
| Zoll Services LLC (a/k/a Zoll Lifecor Corp) | $110 |
| Pfizer Inc. | $106 |
| Novo Nordisk Inc | $103 |
| Novartis Pharmaceuticals Corporation | $65.83 |
| Food and Beverage | $1,295 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 6 companies. The companies reported $233,653 in research payments for these studies, mostly to the institutions running them.
- A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate …
AstraZeneca Pharmaceuticals LP - Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
Novartis Pharmaceuticals Corporation - A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)
Novartis Pharmaceuticals Corporation - A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Diseas…
AstraZeneca Pharmaceuticals LP - A Phase III Randomised Doubleblind Study to Evaluate the Effect of Balcinrenone Dapagliflozin Compared with Dapagliflozin on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and…
AstraZeneca Pharmaceuticals LP - A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Eli Lilly and Company · Completed · NCT04255433 - A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a)…
Novartis Pharmaceuticals Corporation - Study name not reported
Ionis Pharmaceuticals, Inc. - A multi-center, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated lipoprotein(a)
Novartis Pharmaceuticals Corporation - A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.